Invivyd (IVVD) Competitors $0.40 -0.05 (-11.68%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IVVD vs. GOSS, LFCR, LXEO, CRDF, INBX, DMAC, ZNTL, SLN, PROC, and MGNXShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Gossamer Bio (GOSS), Lifecore Biomedical (LFCR), Lexeo Therapeutics (LXEO), Cardiff Oncology (CRDF), Inhibrx (INBX), DiaMedica Therapeutics (DMAC), Zentalis Pharmaceuticals (ZNTL), Silence Therapeutics (SLN), Procaps Group (PROC), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Gossamer Bio Lifecore Biomedical Lexeo Therapeutics Cardiff Oncology Inhibrx DiaMedica Therapeutics Zentalis Pharmaceuticals Silence Therapeutics Procaps Group MacroGenics Invivyd (NASDAQ:IVVD) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Does the media refer more to IVVD or GOSS? In the previous week, Invivyd had 4 more articles in the media than Gossamer Bio. MarketBeat recorded 8 mentions for Invivyd and 4 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.11 beat Invivyd's score of 1.03 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, IVVD or GOSS? Gossamer Bio has higher revenue and earnings than Invivyd. Gossamer Bio is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$11.56M4.13-$198.64M-$1.96-0.20Gossamer Bio$105.32M1.99-$179.82M-$0.32-2.88 Is IVVD or GOSS more profitable? Gossamer Bio's return on equity of -127.28% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets InvivydN/A -155.33% -114.88% Gossamer Bio N/A -127.28%-22.12% Which has more volatility and risk, IVVD or GOSS? Invivyd has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Do insiders and institutionals have more ownership in IVVD or GOSS? 70.4% of Invivyd shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 17.9% of Invivyd shares are held by insiders. Comparatively, 5.0% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate IVVD or GOSS? Invivyd currently has a consensus price target of $7.89, suggesting a potential upside of 1,875.83%. Gossamer Bio has a consensus price target of $9.20, suggesting a potential upside of 896.86%. Given Invivyd's stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than Gossamer Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer IVVD or GOSS? Gossamer Bio received 135 more outperform votes than Invivyd when rated by MarketBeat users. However, 80.00% of users gave Invivyd an outperform vote while only 66.23% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformInvivydOutperform Votes1680.00% Underperform Votes420.00% Gossamer BioOutperform Votes15166.23% Underperform Votes7733.77% SummaryGossamer Bio beats Invivyd on 10 of the 18 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.75M$2.95B$5.29B$8.77BDividend YieldN/A1.94%5.07%4.00%P/E Ratio-0.2047.8186.3216.79Price / Sales4.13396.341,119.23113.74Price / CashN/A182.3143.2437.77Price / Book0.256.405.094.87Net Income-$198.64M-$41.49M$121.83M$227.32M7 Day Performance-21.73%-8.29%-4.05%-4.55%1 Month Performance-27.02%-4.46%-0.23%-0.27%1 Year Performance-90.58%-4.09%24.06%12.93% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.422 of 5 stars$0.40-11.7%$7.89+1,875.8%-89.3%$47.75M$11.56M-0.20100Analyst ForecastShort Interest ↑Positive NewsGOSSGossamer Bio4.39 of 5 stars$1.12+9.8%$9.20+721.4%-0.2%$253.80M$105.32M-3.50180Short Interest ↓Positive NewsGap UpLFCRLifecore Biomedical3.2649 of 5 stars$6.79-10.9%$8.00+17.8%-8.4%$250.06M$128.44M84.88690Short Interest ↑Analyst RevisionLXEOLexeo Therapeutics2.6392 of 5 stars$7.38+1.2%$23.80+222.5%-59.1%$244.03M$650,000.00-2.3458Gap DownCRDFCardiff Oncology2.9382 of 5 stars$4.69-0.2%$10.33+120.3%+113.6%$239.82M$688,000.00-4.9920Positive NewsINBXInhibrx1.4247 of 5 stars$16.47+2.0%N/A-59.3%$238.42M$1.57M0.00166News CoverageDMACDiaMedica Therapeutics1.7094 of 5 stars$5.49-1.3%$7.00+27.5%+76.3%$234.76MN/A-9.8020Short Interest ↑News CoverageZNTLZentalis Pharmaceuticals2.3686 of 5 stars$3.21-0.9%$10.00+211.5%-80.7%$228.76M$40.56M-1.29160Short Interest ↓Gap DownSLNSilence Therapeutics2.586 of 5 stars$7.56+2.3%$57.20+656.6%-66.2%$226.26M$16.25M-4.82100PROCProcaps Group2.0646 of 5 stars$1.99-11.6%N/A-64.4%$224.51M$414.10M3.835,500Short Interest ↓Positive NewsGap UpHigh Trading VolumeMGNXMacroGenics3.8389 of 5 stars$3.50+1.2%$7.63+117.9%-70.3%$219.67M$139.77M-2.22430News CoverageNegative News Related Companies and Tools Related Companies GOSS Competitors LFCR Competitors LXEO Competitors CRDF Competitors INBX Competitors DMAC Competitors ZNTL Competitors SLN Competitors PROC Competitors MGNX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IVVD) was last updated on 1/13/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
